Methylation status and patient characteristics
. | No. of patients . | DAP-kinase methylated, no. (%) . | P . | OR (95% CI) . |
|---|---|---|---|---|
| Age | .1 | — | ||
| Younger than 59 y | 66 | 14 (21) | ||
| 60 y or older | 94 | 30 (31.9) | ||
| Sex | .5 | — | ||
| Female | 75 | 23 (30.7) | ||
| Male | 85 | 21 (24.7) | ||
| Type | .01 | 3.1 (1.4-7.2) | ||
| De novo | 131 | 30 (22.9) | ||
| Therapy-related | 29 | 14 (48.3) | ||
| Cytogenetics | .02 | 3.1 (1.1-8.5) | ||
| Normal | 47 | 6 (12.8) | ||
| Abnormal | 64 | 20 (31.5) | ||
| Cytogenetic risk group | .02 | — | ||
| Favorable | 28 | 10 (35.7) | ||
| Intermediate | 65 | 9 (13.8) | ||
| Unfavorable | 18 | 7 (38.9) | ||
| Myelodysplastic changes | .0004 | 3.7 (1.8-7.5) | ||
| No | 114 | 25 (21.9) | ||
| Yes | 26 | 13 (50) |
. | No. of patients . | DAP-kinase methylated, no. (%) . | P . | OR (95% CI) . |
|---|---|---|---|---|
| Age | .1 | — | ||
| Younger than 59 y | 66 | 14 (21) | ||
| 60 y or older | 94 | 30 (31.9) | ||
| Sex | .5 | — | ||
| Female | 75 | 23 (30.7) | ||
| Male | 85 | 21 (24.7) | ||
| Type | .01 | 3.1 (1.4-7.2) | ||
| De novo | 131 | 30 (22.9) | ||
| Therapy-related | 29 | 14 (48.3) | ||
| Cytogenetics | .02 | 3.1 (1.1-8.5) | ||
| Normal | 47 | 6 (12.8) | ||
| Abnormal | 64 | 20 (31.5) | ||
| Cytogenetic risk group | .02 | — | ||
| Favorable | 28 | 10 (35.7) | ||
| Intermediate | 65 | 9 (13.8) | ||
| Unfavorable | 18 | 7 (38.9) | ||
| Myelodysplastic changes | .0004 | 3.7 (1.8-7.5) | ||
| No | 114 | 25 (21.9) | ||
| Yes | 26 | 13 (50) |
The percentages shown represent the percentage of the total number of patients analyzed in each group. ORs are not given for nonsignificant differences (—; P>.05).